SCHEMBL578809

SCHEMBL578809

NC1C2CCC(CC2)C1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 3/20 0.41
POLB P06746 2/20 0.39
KDM4E B2RXH2 2/20 0.39
APEX1 P27695 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
PMP22 Q01453 1/20 0.39
TFPI2 P48307 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
THPO P40225 1/20 0.39
GABRR1 P24046 1/20 0.36
GRM2 Q14416 9/20 0.34
GRM6 O15303 5/20 0.33
GRM5 P41594 4/20 0.33
GRM3 Q14832 4/20 0.33
GRM4 Q14833 2/20 0.33
GRM8 O00222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610999 1.00 GRM1 (0.41) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL18053340 1.00 GRM1 (0.41) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL20382051 1.00 GRM1 (0.41) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL23611095 1.00 GRM1 (0.41) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL18055930 1.00 GRM1 (0.41) GRM1POLBKDM4EAPEX1TDP1
Hydrochloric Acid SCHEMBL21068146 0.97 GRM1 (0.39) GRM1POLBKDM4EAPEX1TDP1
Hydrochloric Acid SCHEMBL25179204 0.97 GRM1 (0.39) GRM1POLBKDM4EAPEX1TDP1
Hydrochloric Acid SCHEMBL21820830 0.91 GRM2 (0.38) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL21986562 0.85 LMNA (0.41) GRM1POLBKDM4EAPEX1TDP1
SCHEMBL1254906 0.85 LMNA (0.41) GRM1POLBKDM4EAPEX1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3362451-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
US-11535613-B2 Crystal form and salt form of pyridoimidazole compound and preparation method therefor Guangdong Raynovent Biotech Co., Ltd. (CN) 2022-12-27 US disclosed
CN-110446711-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2022-02-15 CN disclosed
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-01-18 US disclosed
EP-3380467-B1 HETEROCYCLIC INDOLES FOR USE IN INFLUENZA VIRUS INFECTION JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-07-07 EP disclosed
CN-108290869-B Heterocyclic indoles for use in influenza virus infection 爱尔兰詹森科学公司 2021-05-18 CN disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 US disclosed
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-23 US disclosed
EP-3763713-A1 CRYSTAL FORM AND SALT FORM OF PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR Guangdong Raynovent Biotech Co., Ltd. (CN) 2021-01-13 EP disclosed
EP-2357181-A1 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases Boehringer Ingelheim International GmbH (DE) 2011-08-17 EP disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 EP disclosed
EP-2027107-A1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-02-25 EP disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 WO disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed
WO-2007132010-A1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof EIF2AK2, POLRMT, ZC3HAV1 GRM1 4819/4885POLB 24/4885KDM4E 2023/4885
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT GRM1 4841/4885POLB 35/4885KDM4E 962/4885
US-11535613-B2 Crystal form and salt form of pyridoimidazole compound and preparation method therefor SLC5A11, SLC39A11, CYP4F11 GRM1 3124/4885POLB 3509/4885KDM4E 3462/4885
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof POLRMT, EIF2AK2, POLM GRM1 4814/4885POLB 12/4885KDM4E 1334/4885
US-20090163467-A1 New compounds CCNA1, MKI67, CCNT1 GRM1 1279/4885POLB 2138/4885KDM4E 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.